Brendan Curti
Overview
Explore the profile of Brendan Curti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Curti B, Crittenden M, Seung S, Fountain C, Payne R, Chang S, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32467299
Background: A pilot study of stereotactic body radiation therapy (SBRT) followed by high-dose interleukin-2 (IL-2) showed a higher than anticipated objective response rate (ORR) among patients with metastatic melanoma (MM)....
12.
Silk A, Kaufman H, Curti B, Mehnert J, Margolin K, McDermott D, et al.
Front Oncol
. 2020 Jan;
9:1483.
PMID: 31998643
High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to...
13.
Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, et al.
J Immunother Cancer
. 2019 Aug;
7(1):225.
PMID: 31439037
Background: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. Methods: MEDI0680 was...
14.
Clark J, Singh J, Ernstoff M, Lao C, Flaherty L, Logan T, et al.
J Immunother Cancer
. 2018 Jul;
6(1):76.
PMID: 30053905
Background: Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in...
15.
Curti B, Daniels G, Mcdermott D, Clark J, Kaufman H, Logan T, et al.
J Immunother Cancer
. 2017 Dec;
5(1):102.
PMID: 29254506
Background: Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact...
16.
Siefker-Radtke A, Curti B
Nat Rev Urol
. 2017 Dec;
15(2):112-124.
PMID: 29205200
Immunotherapy has been used in localized urothelial carcinoma for decades, especially in the treatment of superficial disease, in which instillation of BCG is a commonly used treatment option. Clinical investigations...
17.
Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, et al.
Melanoma Res
. 2017 Nov;
28(1):44-51.
PMID: 29176501
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We...
18.
Sckisel G, Mirsoian A, Minnar C, Crittenden M, Curti B, Chen J, et al.
J Immunother Cancer
. 2017 Apr;
5:33.
PMID: 28428882
Background: Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T...
19.
Bell R, Gough M, Seung S, Jutric Z, Weinberg A, Fox B, et al.
Oral Oncol
. 2017 Feb;
66:e3.
PMID: 28202215
No abstract available.
20.
Clark J, Wong M, Kaufman H, Daniels G, Morse M, Mcdermott D, et al.
Clin Genitourin Cancer
. 2016 Dec;
15(1):31-41.e4.
PMID: 27916626
Background: This analysis describes the outcome for patients who received targeted therapy (TT) prior to or following high-dose interleukin-2 (HD IL-2). Patients And Methods: Patients with renal cell carcinoma (n ...